Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

NCT05279235 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

290

Enrollment

INDUSTRY

Sponsor class

Stopped Development strategy adjustment

Conditions

Moderate to Severe COVID-19

Interventions

DRUG: JT001
DRUG: JT001 placebo
DRUG: Favipiravir
DRUG: Favipiravir placebo

Sponsor

Shanghai Vinnerna Biosciences Co., Ltd.

Collaborators

[object Object]